Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: J Nucl Med. 2010 May 19;51(6):942–950. doi: 10.2967/jnumed.109.071290

Figure 4.

Figure 4

(A) Time-activity curve and uptake values of 86Y-CHX-A″-DTPA-panitumumab in selected organs of female athymic (NCr) nu/nu mice bearing human colorectal carcinoma LS-174T xenografts assessed through quantitative small animal PET imaging. (B) Comparative time-activity curves of 86Y-CHX-A″-DTPA-panitumumab in female athymic (NCr) nu/nu mice bearing LS-174T, A431 and PC-3 tumor xenografts. (C) Correlation between organ % ID/g values assessed through in vivo biodistribution studies and quantitative small animal PET imaging. All uptake values derived from PET studies are expressed as % ID/cc. Data represent the mean value ± SEM from three determinations.

*Receptor blocking studies performed by co-injecting 0.1 mg panitumumab with the radiotracer.